How Analysts Feel About Akcea Therapeutics, Inc. (AKCA) After Today’s Big Increase?

April 22, 2018 - By Nellie Frank

The stock of Akcea Therapeutics, Inc. (NASDAQ:AKCA) is a huge mover today! The stock increased 8.77% or $2.11 during the last trading session, reaching $26.18. About 438,606 shares traded or 23.17% up from the average. Akcea Therapeutics, Inc. (NASDAQ:AKCA) has 0.00% since April 22, 2017 and is . It has underperformed by 11.55% the S&P500.
The move comes after 8 months positive chart setup for the $1.75B company. It was reported on Apr, 22 by We have $27.75 PT which if reached, will make NASDAQ:AKCA worth $104.82M more.

Analysts await Akcea Therapeutics, Inc. (NASDAQ:AKCA) to report earnings on May, 28. After $-0.26 actual EPS reported by Akcea Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 30.77 % negative EPS growth.

Akcea Therapeutics, Inc. (NASDAQ:AKCA) Ratings Coverage

Among 2 analysts covering Akcea Therapeutics Inc (NASDAQ:AKCA), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Akcea Therapeutics Inc had 3 analyst reports since October 31, 2017 according to SRatingsIntel. The stock has “Buy” rating by Stifel Nicolaus on Tuesday, November 7. Stifel Nicolaus maintained it with “Buy” rating and $19.0 target in Tuesday, October 31 report.

Akcea Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with cardiometabolic diseases caused by lipid disorders in the United States and internationally. The company has market cap of $1.75 billion. It develops Volanesorsen, which has completed Phase 3 clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase 3 clinical study for the treatment of familial partial lipodystrophy. It currently has negative earnings. The firm also develops AKCEA-APO-LRx, which has completed Phase 2b clinical study for treating patients suffering with hyperlipoproteinemia; AKCEA-ANGPTL3-LRx that has completed Phase 1/2 clinical study for the treatment of multiple lipid disorders; and AKCEA-APOCIII-LRx, which is in Phase 1/2 study for the treatment of cardiovascular disease driven by high triglycerides.

Akcea Therapeutics, Inc. (NASDAQ:AKCA) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.